CST: 26/09/2016 12:19:10   

Patented Medicine Prices Review Board Will Hear Allegations of Breach of Reporting Requirements for Leukemia Drug

185 Days ago

OTTAWA, ONTARIO--(Marketwired - Mar 24, 2016) - Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Baxalta Canada Corporation failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations. The proceeding relates to the medicine Oncaspar, which is sold in Canada under Health Canada's Special Access Programme and is used in the treatment of patients with Acute Lymphoblastic Leukemia.

The purpose of the hearing is to receive evidence and argument of Board Staff, Baxalta Canada Corporation, and any interveners regarding allegations that Baxalta Canada Corporation is in breach of its reporting requirements. The date, time, and location of the public hearing will be set and confirmed at a later date.

Those wishing to participate in this proceeding must apply to the Board for leave to intervene by May 2, 2016. For more information on the application process, please contact:

Guillaume Couillard
Director, Board Secretariat
Patented Medicine Prices Review Board
Box L40, 333 Laurier Avenue West, Suite 1400
Ottawa, Ontario K1P 1C1
Telephone: 613-954-8299
Fax: 613-952-7626
E-mail: Guillaume.Couillard@pmprb-cepmb.gc.ca

Quick Facts

  • The Patented Medicine Prices Review Board is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive, and provides stakeholders with price, cost, and utilization information to help them make timely and knowledgeable drug pricing, purchasing, and reimbursement decisions.
  • Patentees must file price and sales information with the Patented Medicine Prices Review Board at introduction, and twice a year afterward, for each strength of each dosage form of each patented medicine sold in Canada.
  • Board Staff review the prices patentees charge for each individual patented drug product sold in Canadian markets on an ongoing basis to ensure their prices are not excessive.
  • If the Board Panel finds a patentee to be in breach of its reporting requirements, the Board Panel may order the patentee to provide the Patented Medicine Prices Review Board with the required pricing and sales information.

Related Products

Additional Links

Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Sofie.McCoy-Astell@pmprb-cepmb.gc.ca